Endogenous opioids modify dyspnoea during treadmill exercise in patients with COPD

European Respiratory Journal

Volumn 33, Issue 4, 2009, Pages 771-777

  Mahler, D A ^a,b   Murray, J A ^c   Waterman, L A ^b   Ward, J ^b   Kraemer, W J ^d   Zhang, X ^a   Baird, J C ^a,e  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^c UNITY HEALTH SYSTEM   (United States)

^d UNIVERSITY OF CONNECTICUT   (United States)

^e Psychological Applications   (United States)

Author keywords

endorphin immunoreactivity; Chronic obstructive pulmonary disease; Continuous ratings of breathlessness; Naloxone; Treadmill exercise

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ENDORPHIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; NALOXONE; SALBUTAMOL; SODIUM CHLORIDE; THEOPHYLLINE;

ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD; CATHETERIZATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HORMONE BLOOD LEVEL; HUMAN; IMMUNOREACTIVITY; MALE; OUTCOME ASSESSMENT; OXYGEN CONSUMPTION; PERCEPTION; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX RATIO; STRESS; TREADMILL EXERCISE; VEIN;

ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ALBUTEROL; BETA-ENDORPHIN; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; DYSPNEA; EXERCISE TEST; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; NALOXONE; NARCOTIC ANTAGONISTS; OPIOID PEPTIDES; OXYGEN CONSUMPTION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPIROMETRY; THEOPHYLLINE;

EID: 63849244686     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00145208     Document Type: Article

References (31)

1. O'Donnell DE, Banzett RB, Carrieri-Kohlman V, et al. Pathophysiology of dyspnea in chronic obstructive pulmonary disease: a roundtable. ProcAm Thorac Soc 2007; 4:145-168.
2. Light RW, Muro JR, Sato RI, Stansbury DW, Fischer CE, Brown SE. Effects of oral morphine on breathlessness and exercise tolerance in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1989; 139: 126-133.
3. Woodcock AA, Gross ER, Gellert A, Shah S, Johnson M, Geddes DM. Effects of dihydrocodeine, alcohol, and caffeine on breathlessness and exercise tolerance in patients with chronic obstructive lung disease and normal blood gases. N Engl J Med 1981; 305: 1611-1616.
4. Santiago TV, Edelman NH. Opioids and breathing. J Appl Physiol 1985; 59: 1675-1685.
5. Kirsch JL, Muro JR, Stansbury DW, Fischer CE, Monfore R, Light RW. Effect of naloxone on maximal exercise performance and control of ventilation in COPD. Chest 1989; 96: 761-766.
6. Bertley J, VanVugt DA, Webb KA, O'Donnell DE. Exertional breathlessness in severe chronic airflow limitation (CAL): perceptual responses to endogenous opioid blockade. Am J Respir Crit Care Med 1995; 151: A409.
7. Simon PM, Pope A, Lahive K, et al. Naloxone does not alter response to hypercapnia or resistive loading in chronic obstructive pulmonary disease. Am Rev Respir Dis 1989; 139: 134-138.
8. Santiago TV, Remolina C, Scoles V 3rd, Edelman NH., Endorphins and the control of breathing. Ability of naloxone to restore flow-resistive load compensation in chronic obstructive pulmonary disease. N Engl J Med 1981; 304: 1190-1195.
9. Man WD, Soliman MG, Gearing J, et al. Symptoms and quadriceps fatigability after walking and cycling in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 168: 562-567.
10. Pepin V, Saey D, Whittom F, LeBlanc P, Maltais F. Walking versus cycling: sensitivity to bronchodilation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172: 1517-1522.
11. Fierro-Carrion G, Mahler DA, Ward J, Baird JC. Comparison of continuous and discrete measurements of dyspnea during exercise in patients with COPD and normal subjects. Chest 2004; 125: 77-84.
12. Murray JA, Waterman L, Ward J, Kraemer WJ, Mahler DA. Role of endorphins in the perception of breathlessness during treadmill exercise in COPD. Am J Respir Crit Care Med 2008; 177: A1000.
13. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176: 532-555.
14. Mahler DA, Waterman LA, Ward J, McCusker C, ZuWallack R, Baird JC. Validity and responsiveness of the self-administered computerized versions of the baseline and transition dyspnea indexes. Chest 2007; 132: 1283-1290.
15. Ofir D, Laveneziana P, Webb KA, Lam YM, O'Donnell DE. Mechanisms of dyspnea during cycle exercise in symptomatic patients with GOLD stage I chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177: 622-629.
16. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. Am J Respir Crit Care Med 1995; 152: S77-S121.
17. Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981; 123: 659-664.
18. Mahler DA, Cunningham LN, Skrinar GS, Kraemer WJ, Colice GL. β-Endorphin activity and hypercapnic ventilatory responsiveness after marathon running. J Appl Physiol 1989; 66: 2431-2436.
19. Mahler DA, Fierro-Carrion G, Mejia-Alfaro R, Ward J, Baird JC. Responsiveness of continuous ratings of dyspnea during exercise in patients with COPD. Med Sci Sports Exerc 2005; 37: 529-535.
20. O'Donnell DE, Lam M, Webb KA. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 158: 1557-1565.
21. Thorén P, Floras JS, Hoffmann P, Seals DR. Endorphins and exercise: physiological mechanisms and clinical implications. Med Sci Sports Exerc 1990; 22: 417-428.
22. Moss IR, Scarpelli EM. β-Endorphin central depression of respiration and circulation. JApplPhysiol 1981; 50:1011-1016.
23. Santiago TV, Johnson J, Riley DJ, Edelman NH. Effects of morphine on ventilatory response to exercise. J Appl Physiol 1979; 47: 112-118.
24. Murray JA, Waterman LA, Ward J, Baird JC, Mahler DA. Perceptual and physiological responses during treadmill and cycle exercise in patients with COPD. Chest 2008; [Epub ahead of print PMID: 18753470].
25. Bellofiore S, Di Maria GU, Privitera S, Sapienza S, Milic-Emili J, Mistretta A. Endogenous opioids modulate the increase in ventilatory output and dyspnea during severe acute bronchoconstriction. Am Rev Respir Dis 1990; 142: 812-816.
26. Akiyama Y, Nishimura M, Kobayashi S, et al. Effects of naloxone on the sensation of dyspnea during acute respiratory stress in normal adults. J Appl Physiol 1993; 74: 590-595.
27. O'Donnell DE, Fluge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004; 23: 832-840.
28. O'Donnell DE, Sciurba F, Celli B, et al. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest 2006; 130: 647-656.
29. Tabona MV, Ambrosino N, Barnes PJ. Endogenous opiates and the control of breathing in normal subjects and patients with chronic airflow obstruction. Thorax 1982; 37: 834-839.
30. Santiago TV, Sheft SA, Khan AU, Edelman NH. Effect of naloxone on the respiratory responses to hypoxia in chronic obstructive pulmonary disease. Am Rev Respir Dis 1984; 130: 183-186.
31. Olausson B, Eriksson E, Ellmarker L, Rydenhag B, Shyu BC, Andersson SA. Effects of naloxone on dental pain threshold following muscle exercise and low frequency transcutaneous nerve stimulation: a comparative study in man. Acta Physiol Scand 1986; 126: 299-305.